Myovant’s deal with Pfizer for $650M up front is the latest sign women’s health is back

Pfizer’s partnership with Myovant sends another signal that plenty of opportunity still exists in women’s health, despite recent pharma exits.

In teaming up with Pfizer Inc. (NYSE:PFE) to develop and commercialize relugolix, Myovant Sciences GmbH (NYSE:MYOV) will receive an upfront payment of $650 million and is eligible for $200 million in regulatory milestones around a combination tablet, and tiered sales milestones for a total deal value of up to $4.2 billion...